Chairperson appointed for Fusion Pharmaceuticals

Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, has named Barbara Duncan as chairperson of the Fusion Board of Directors. Duncan brings to the board more than 25 years’ of biopharma experience, including as former chief financial officer of Intercept Pharmaceuticals Inc. and member of several boards of directors within the biotechnology industry. She replaces Damian Lamb as Fusion’s chairperson.

“Barbara’s breadth and depth of industry, director and financial knowledge will be invaluable to Fusion as we solidify our position as a leader in the radiopharmaceutical space and utilize our Targeted Alpha Therapies (TAT) platform to grow our pipeline,” says CEO John Valliant. “Additionally, her leadership experience and strategic approach to business development and corporate governance will provide important organizational and operational guidance.

Barbara Duncan

“We thank Damian for his years of service on the board. Over his tenure, his direction and strategic guidance have been instrumental to us as we developed our platform and transitioned from a newly established biotech to a publicly traded company.”

Duncan served as the chief financial officer of Intercept Pharmaceuticals Inc. from 2009 to June 2016. Prior to Intercept, she was chief financial officer of DOV Pharmaceutical Inc. from 2001 to 2006 and was CEO and a member of the company’s board of directors from 2007 to 2009.

Duncan is on the boards of directors and various committees of Adaptimmune Therapeutics plc, Atea Pharmaceuticals Inc., Jounce Therapeutics Inc., ObsEva SA, and Ovid Therapeutics Inc. She holds an MBA from the Wharton School of Business and a B.S. from Louisiana State University.